Latest Articles

Publication Date
All News Scientific
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - Defense World

Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan Defense World

Published: Jan. 10, 2026, 6:12 a.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com UK

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com UK

Published: Jan. 9, 2026, 2:25 p.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com

Published: Jan. 9, 2026, 1:59 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 9, 2026, 6:18 a.m.
Read Full Article
Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga

Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) Benzinga

Published: Jan. 8, 2026, 7:02 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 8, 2026, 12:53 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b - GlobeNewswire

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b GlobeNewswire

Published: Jan. 8, 2026, 12:30 p.m.
Read Full Article
Onconic Therapeutics wins IND approval for phase 1b–2 gastric cancer trial in Korea - CHOSUNBIZ - Chosunbiz

Onconic Therapeutics wins IND approval for phase 1b–2 gastric cancer trial in Korea - CHOSUNBIZ Chosunbiz

Published: Dec. 17, 2025, 1:04 a.m.
Read Full Article
Metri Bio: $5 Million Pre-Seed Secured To Advance Next-Generation Endometriosis Therapeutics - Pulse 2.0

Metri Bio: $5 Million Pre-Seed Secured To Advance Next-Generation Endometriosis Therapeutics Pulse 2.0

Published: Dec. 10, 2025, 12:36 p.m.
Read Full Article
Metri Bio raises US$5m for endo therapeutics - FemTech World

Metri Bio raises US$5m for endo therapeutics FemTech World

Published: Dec. 4, 2025, 9:05 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!